Earnings Summary

Caribou Biosciences’s revenue fell -3.63% since last year same period to $3.56Mn in the Q4 2023. On a quarterly growth basis, Caribou Biosciences has generated -84.96% fall in its revenue since last 3-months.

Caribou Biosciences’s net profit fell -27.85% since last year same period to $-34.51Mn in the Q4 2023. On a quarterly growth basis, Caribou Biosciences has generated -244.98% fall in its net profits since last 3-months.

Caribou Biosciences’s net profit margin fell -32.66% since last year same period to -969.79% in the Q4 2023. On a quarterly growth basis, Caribou Biosciences has generated -2194.25% fall in its net profit margins since last 3-months.

Caribou Biosciences’s earning per share (EPS) estimates for the current quarter stand at -0.41 - a -10.95% fall from last quarter’s estimates.

Caribou Biosciences’s earning per share (EPS) estimates for the current year stand at -0.41.

Caribou Biosciences’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2024. This indicates that the Caribou Biosciences has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.